Retatrutide + Cagrilintide Blend: Dosage, Benefits & Side Effects

By Peptide Assistant Editorial Team · · · 9 sources cited

Overview

Reta-Cagri Blend combines retatrutide, a triple-agonist GLP-1/GIP/glucagon receptor peptide, with cagrilintide, a long-acting amylin analog. This combination targets multiple metabolic pathways simultaneously — appetite suppression, insulin sensitization, glucagon-mediated fat oxidation, and gastric emptying regulation. The blend represents a next-generation approach to obesity pharmacotherapy, leveraging synergistic mechanisms that individually have shown dramatic weight loss in clinical trials.

Mechanism of Action

Retatrutide activates three distinct receptors: GLP-1R, GIPR, and the glucagon receptor (GCGR). GLP-1R activation suppresses appetite via hypothalamic satiety centers and slows gastric emptying, enhancing post-meal fullness. GIPR agonism improves insulin sensitivity and may enhance the central appetite-suppressive effects of GLP-1. The glucagon receptor component is the distinguishing feature — it increases hepatic fat oxidation, stimulates energy expenditure, and promotes thermogenesis, addressing the metabolic slowdown that often accompanies caloric restriction. Cagrilintide is a long-acting analog of amylin, a hormone co-secreted with insulin from pancreatic beta cells. It binds to the amylin receptor (AMY1/AMY3) in the area postrema and lateral parabrachial nucleus, reducing meal size and promoting satiety through a distinct pathway from GLP-1. It also slows gastric emptying independently and reduces postprandial glucagon secretion. Together, these compounds create a four-receptor assault on obesity — GLP-1R, GIPR, GCGR, and amylin receptors — covering appetite, satiety, energy expenditure, and glucose regulation simultaneously. In diet-induced obese male rats, the combination reduced body weight and food intake more than either drug alone; it has not been tested in humans.

Retatrutide + Cagrilintide Blend Benefits: What the Research Shows

  • Retatrutide Phase II trial (2023, NEJM) showed up to 24.2% body weight loss at 48 weeks at the 12 mg dose — the highest recorded for any obesity drug at that time
  • Cagrilintide Phase II trial (2021, Lancet) demonstrated 10.8% weight loss at 4.5 mg weekly over 26 weeks as monotherapy
  • The CagriSema concept (cagrilintide + semaglutide) achieved ~15.6% weight loss in 32 weeks in Phase II, validating multi-mechanism approaches
  • Retatrutide's glucagon activity may reduce liver fat by stimulating hepatic fatty acid oxidation; the authors of its Phase II liver sub-study noted more liver fat lowering than reported for GLP-1 mono-agonists or tirzepatide, though not in a head-to-head comparison
  • Retatrutide significantly reduced liver fat content (up to 82.4% relative reduction at 24 weeks) in a Phase II sub-study
  • Amylin analogs have shown independent weight loss effects additive to GLP-1RA therapy in rodent and human studies

Retatrutide + Cagrilintide Blend Dosage

  • Starting dose: typically low-dose escalation beginning at 0.5 mg retatrutide / 0.25 mg cagrilintide weekly
  • Dose titration over 4–8 weeks, increasing every 2–4 weeks based on tolerance
  • Maintenance doses vary; retatrutide component may reach 8–12 mg weekly in aggressive protocols
  • Administered as a single subcutaneous injection weekly, typically in the abdomen or thigh
  • Inject at the same time each week for consistent blood levels
  • Best administered in the morning or early afternoon to align appetite suppression with waking hours
  • Cycle length: ongoing while weight loss goals are being pursued; no established cycling protocol
  • GI side effects are dose-limiting — slow titration is essential to minimize nausea and vomiting
Peptide calculator: get your dose in syringe units →

Disclaimer: Dosing information is compiled from research literature and community protocols for educational purposes only. This is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol.

Retatrutide + Cagrilintide Blend Side Effects & Safety

Known Side Effects

  • Nausea is the most common side effect, particularly during dose escalation (in trials of each drug alone: 14–28% on retatrutide and 20–47% on cagrilintide; the combination has not been tested in humans)
  • Vomiting and diarrhea are frequent, especially at higher doses or with rapid titration
  • Decreased appetite — expected pharmacological effect but can become excessive
  • Constipation from slowed gastric motility
  • Injection site reactions including redness, swelling, and itching
  • Potential for gallbladder events (cholelithiasis) with rapid weight loss, consistent with other GLP-1 class agents
  • Dose-dependent heart rate increases observed in retatrutide trial participants, peaking at 24 weeks and declining thereafter

Safety Profile

Neither retatrutide nor cagrilintide is FDA-approved (FDA statement current October 2026), and no human trial of the two together has been published or registered; the only study of the combination is in rats. The individual components have shown acceptable safety profiles in Phase II trials, but long-term data is lacking. GI side effects are the primary tolerability concern and are managed through slow dose escalation. As with all GLP-1 class agents, there is a theoretical concern about medullary thyroid carcinoma based on rodent studies, though no human cases have been attributed to these drugs. Patients with a personal or family history of MTC or MEN2 should avoid this class. Pancreatitis risk has been flagged for GLP-1 agonists generally, though causation remains debated. Renal function should be monitored, as severe dehydration from GI side effects can impair kidney function. This blend should not be used during pregnancy, in patients with gastroparesis, or in those with a history of eating disorders where further appetite suppression could be harmful.

What to Expect

Week 1–2: Mild appetite reduction becomes noticeable, particularly around meal times. Some nausea is common, especially after larger meals. Week 3–4: Appetite suppression strengthens considerably as doses escalate. Most users report eating 30–50% less without conscious effort. Nausea typically peaks then begins to improve. Week 5–8: Weight loss becomes measurable, typically 3–6% of body weight. Energy levels stabilize. GI side effects generally diminish as the body adjusts. Week 9–16: Continued steady weight loss of 1–2 lbs per week. Many users report reduced cravings for high-calorie foods and improved relationship with portion sizes. Week 16+: Weight loss continues but rate may slow. With retatrutide alone, weight loss at 24 weeks reached 17.5% at the highest dose in the Phase II trial; there are no human data for the combination. Body composition improvements become visible.

Common Stacks

Storage & Handling

Store lyophilized powder at -20°C for long-term storage or 2–8°C (refrigerated) for up to 12 months. Once reconstituted with bacteriostatic water, store at 2–8°C and use within 4–6 weeks. Do not freeze reconstituted solution. Protect from light. The blend is typically supplied as a single lyophilized vial; reconstitute slowly by directing bacteriostatic water down the side of the vial and swirl gently — do not shake.

Pricing & Available Variants

$129.99price range
5mg+5mg

Prices sourced from peptides.gg marketplace. Prices may vary.

References

  1. Petersen J, Merrild C, Holm SK, et al. Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats. Nat Metab. 2026.
  2. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023.
  3. Lau DCW, Erichsen L, Francisco AM, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021.
  4. Bellido V, le Roux CW, Ekinci EI, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet. 2026.
  5. Frias JP, Deenadayalan S, Erichsen L, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet. 2023.
  6. Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024.
  7. Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022.
  8. Le Foll C, Lutz TA. Amylin: A Multi-Functional Pancreatic Hormone-A Review. Diabetes Obes Metab. 2026.
  9. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. U.S. Food and Drug Administration. 2026.

Related Peptides

Track Retatrutide + Cagrilintide Blend in Your Protocol

Log your Retatrutide + Cagrilintide Blend doses, track consistency, and monitor your protocol with Peptide Assistant — completely free.

Start Tracking Free